Using transgenic mice [71, 72] and rats [73], these studies could provide mechanistic insights, e.g. that β-amyloid pathology causes a biomarker profile observed in AD, even in the absence of tau aggregation and neuronal losses [73]. The gene discussed is MAPT; the disease is Alzheimer disease.